Effect of preoperative administration of intravenous parecoxib on postoperative morphine consumption after video-assisted thoracoscopic surgery

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20171213002

Enrollment

Registered

2017-12-13

Start date

2017-01-06

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer, Lung mass, spontaneous pneumothorax, emphysema thoracis Intravenous parecoxib

Interventions

parecoxib IV for preemptive and perioperative analgesia in VAT surgery,placebo is a NSS solution

Active Comparator Drug,Placebo Comparator Drug

parecoxib,placebo

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. patients who undergoing elective video-assisted thoracoscopic surgery 2. Age between 18-65 years old 3. ASA status I-III

Exclusion criteria

Exclusion criteria: - History of chronic analgesic use (nonsteroidal anti-inflammatory drugs; NSAIDS, opioids, or paracetamol) - Presence of a chronic pain disorder (i.e. back pain, cancer, arthritis) - Inability to use the PCA device - Allergy to the study drugs: parecoxib and morphine - Neurological disease or major psychiatric disorder - Pregnancy

Design outcomes

Primary

Measure	Time frame
Postoperative morphine consumption in each group 24-h postoperatively Mg of morphine by IV PCA history device	—

Secondary

Measure	Time frame
Pain score at rest and during cough in different time 2, 6, 12 and 24 h postoperatively pain score at 2, 6, 12 and 24 h postop both at rest and on cough	—

Countries

Thailand

Contacts

Public ContactSarinya Chanthawong

Faculty of Medicine, Khon Kaen University

tsukire@gmail.com043348390

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026